Survodutide
Dual glucagon / GLP-1 receptor agonist (BI 456906) — investigational; not FDA-approved.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. Survodutide (developmental code BI 456906) is a dual glucagon receptor / GLP-1 receptor agonist. PubChem CID 171378821; formula C192H289N47O61 / MW ~4232; CAS 2805997-46-8. It has no approved drug indication in the jurisdictions this drawer treats as labeled (US/EU). Off-label does not apply. There is no label to be off of. It is not mazdutide (also dual GLP-1/glucagon, different molecule / different CID/CAS/codes), not retatrutide (triple agonist), and not dulaglutide, semaglutide, or tirzepatide.
Bottom line
PubMed holds discovery/preclinical pharmacology, phase 2 obesity and type 2 diabetes programs, and a phase 2 MASH-with-fibrosis trial. Those are investigational human objects. Post-hoc blood-pressure and subgroup analyses stay inside the parent trial object. They do not create a labeled cardiometabolic indication.
Papers
Investigational — discovery / preclinical
PMID 36356832 — Zimmermann 2022
Tested: discovery and preclinical pharmacology of BI 456906 as a GCGR/GLP-1R dual agonist with anti-obesity efficacy in laboratory models.
Does not show: a controlled human obesity or MASH result, or a labeled indication.
Investigational — obesity (phase 2)
PMID 38330987 — le Roux 2024
Tested: once-weekly injectable survodutide versus placebo for body weight in adults with obesity (randomized, double-blind, placebo-controlled, dose-finding phase 2).
Does not show: a labeled obesity indication, a type 2 diabetes primary claim (see Blüher), or equivalence to mazdutide or retatrutide.
PMID 39821928 — le Roux 2025
Tested: sex and baseline-BMI subgroup analysis inside the phase 2 obesity trial of survodutide (BMI ≥27 kg/m² enrollment frame).
Does not show: a new independent pivotal trial, or a labeled claim.
PMID 39582349 — le Roux 2025
Tested: post-hoc blood-pressure outcomes from the randomized phase 2 obesity program of survodutide.
Does not show: a dedicated cardiovascular-outcomes trial, or a labeled hypertension indication.
Investigational — type 2 diabetes (phase 2)
PMID 38095657 — Blüher 2024
Tested: dose-response effects of survodutide versus placebo and versus open-label semaglutide on HbA1c and body weight in people with type 2 diabetes (phase 2).
Does not show: a labeled T2D indication, that survodutide equals semaglutide, or an obesity-without-diabetes result as the primary object.
Investigational — MASH / fibrosis (phase 2)
PMID 38847460 — Sanyal 2024
Tested: once-weekly injectable survodutide versus placebo for metabolic dysfunction–associated steatohepatitis with fibrosis (randomized phase 2).
Does not show: a labeled MASH indication, or a substitute for the obesity or T2D phase 2 objects.
Secondary / context
PMID 40963161 — Arun 2025
Tested: narrative review of survodutide as an emerging dual GLP-1/glucagon agonist in cardiometabolic care.
Does not show: a new primary randomized result, or an approved indication.
What is not established
An approved obesity, type 2 diabetes, or MASH indication. Phase 3 confirmatory labeled claims. Interchangeability with mazdutide, retatrutide, dulaglutide, semaglutide, or tirzepatide. That post-hoc BP or subgroup analyses equal a CVOT. A non-trial preparation is not BI 456906 trial material.
Selected sources
36356832 38330987 38095657 38847460 39821928 39582349 40963161
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.